Stephen Mandel's Lone Pine Capital Invests in Boston Scientific Corporation
Lone Pine Capital, managed by Stephen Mandel, has added Boston Scientific Corporation (BSX) to its 13F portfolio with a stake of over 200,000 shares. Boston Scientific reported Q1 2026 revenue of $5.20 billion and $0.80 EPS, but lowered full-year guidance, prompting mixed market reactions. The company's Cardiovascular segment showed strong 11.2% organic growth, and its Pulsed Field Ablation platform and WATCHMAN device are gaining traction.
Tickers: $BSX
Topics: Boston Scientific Corporation Guidance Adjustment Hedge Fund Activity Medical Device Industry Pulsed Field Ablation Q1 Earnings WATCHMAN Device